Bristol-Myers Squibb: Not As Cheap As It Might Seem

Group 1 - Bristol-Myers Squibb (NYSE: BMY) is recognized as one of the largest pharmaceutical companies globally, attracting significant attention from value investors recently [1] - BMY shares are perceived to be deeply discounted when compared to the overall U.S. stock market [1] Group 2 - Ian Bezek, a former hedge fund analyst, has extensive experience in conducting on-the-ground research in Latin American markets, focusing on countries like Mexico, Colombia, and Chile [2] - Bezek specializes in identifying high-quality compounders and growth stocks at reasonable prices in the U.S. and other developed markets [2]